Evidence method
Sequential · gp.financial.deposits
3.38% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
VABK · Dec 31, 2025
Virginia National Bankshares Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-128416Bank
Evidence method
Yoy · gp.fundamentals.net_income
13.53% · CORE · VALID
Evidence method
Yoy · gp.financial.interest_income
1.74% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20215/5 normalizedLevel 3Dec 31, 20215/5 normalizedLevel 3Mar 31, 20225/5 normalizedLevel 3Jun 30, 20225/5 normalizedLevel 3Sep 30, 20225/5 normalizedLevel 3Dec 31, 20225/5 normalizedLevel 3Mar 31, 20235/5 normalizedLevel 3Jun 30, 20235/5 normalizedLevel 3Sep 30, 20235/5 normalizedLevel 3Dec 31, 20235/5 normalizedLevel 3Mar 31, 20245/5 normalizedLevel 3Jun 30, 20244/4 normalizedLevel 3Sep 30, 20243/3 normalizedLevel 3Dec 31, 20243/3 normalizedLevel 3Mar 31, 20253/3 normalizedLevel 3Jun 30, 20253/3 normalizedLevel 3Sep 30, 20253/3 normalizedLevel 3Dec 31, 20253/3 normalizedLevel 3Mar 31, 20263/3 normalizedLevel 3Jun 30, 20263/3 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -0.30%
- Current
- 3.38%
- Delta
- 3.68%
- Previous
- -0.52%
- Current
- 13.53%
- Delta
- 14.05%
- Previous
- 0.33%
- Current
- 1.74%
- Delta
- 1.40%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.